
Catch up on the 9 FDA drug approvals most relevant to primary care, including new options for HIV-1 infection, narcolepsy, diabetes, pain management, and more.











Catch up on the 9 FDA drug approvals most relevant to primary care, including new options for HIV-1 infection, narcolepsy, diabetes, pain management, and more.

Real-world phase 4 data show fezolinetant eases menopausal hot flashes and improves sleep, cutting nighttime awakenings by 2.6 by week 12.

The FDA accepted Bayer's sNDA and granted Priority Review to elinzanetant for vasomotor symptoms in women on endocrine therapy for HR+ breast cancer.

Rodica Di Lorenzo, MD, explains why new headaches, migraine with aura, estrogen exposure, smoking, and pregnancy matter in stroke assessment.

The FDA accepted Organon’s MIUDELLA supplemental application, but the proposed change, supporting data, and review timeline remain undisclosed.

Experts weigh GLP-1 therapy's promise for PMOS against the risks of overly rapid weight loss in teenagers.

Experts break down which labs actually change PMOS management and how to avoid diagnostic pitfalls.

Most patients meet PMOS in a primary care office first. Our experts map the referral threshold and argue insulin resistance — not just androgens — should drive how aggressively PCPs treat.

Our expert panel walks through the 2-criteria threshold for adolescents, the "at risk" category, and why untreated menstrual irregularity carries real long-term consequences.

A global consensus just renamed PCOS to PMOS. Our experts explain why the shift moves care beyond the ovaries — and what it means for how clinicians talk to patients today.

Topline phase 2 data showed single-dose ABCL635 reduced moderate-to-severe vasomotor symptom frequency by 83% at week 4.

A McGill University–led team developed a prediction model integrating pregnancy-related factors to identify cardiovascular disease risk in women aged 15 to 45.

Viatris' new once-weekly patch delivers norelgestromin and ethinyl estradiol, with a Pearl Index of 4.14 in the Phase 3 Luminous Study.

FDA cleared Roche’s cobas BV/CV assay to detect bacterial vaginosis and Candida vaginitis from a single vaginal swab sample.

Survey finds nearly 18 million women aged 45 to 64 years are overdue for cancer screening.

Baker explains how smartwatch sleep data can open clinical conversations about menopausal sleep disturbance but emphasizes the importance of patient-reported outcomes.

A 28-day smartwatch study in menopausal women found sleep fragmentation varied from night to night while total sleep time remained stable.

Prenatal sleep expectations predicted postpartum sleep quality above parity and psychiatric history, with postpartum anxiety further worsening outcomes.

Pauline Maki, PhD, reviews data showing over half of elinzanetant's sleep benefit in postmenopausal women is independent of VMS reduction.

From behavioral therapy to NK3 receptor antagonists, Baker outlines an expanding toolkit for menopausal sleep disturbance.

Baker discusses menopause-related sleep disturbances and why early screening and individualized treatment are critical in primary care.

A national survey found high awareness of prenatal health guidance but gaps on alcohol avoidance, iron use, and gestational weight gain.

ACOG 2026: CDC data show many pregnancy-related deaths may be preventable through better care coordination, access, and follow-up.

Despite waning direct impact of COVID-19, US pregnancy-related mortality remains higher than before the pandemic, driven by persistent cardiovascular, infectious, and hemorrhagic causes.

Global experts have redefined PCOS as PMOS, spotlighting metabolic and heart risks to speed diagnosis, reduce stigma, and improve care.